via Fisher Center
New findings suggest a hormone called Lipocalin-2 could be used as a potential treatment for obesity
A hormone that can suppress food intake and increase the feeling of fullness in mice has shown similar results in humans and non-human primates, says a new study published today in eLife.
The hormone, called Lipocalin-2 (LCN2), could be used as a potential treatment in people with obesity whose natural signals for feeling full no longer work.
LCN2 is mainly produced by bone cells and is found naturally in mice and humans. Studies in mice have shown that giving LCN2 to the animals long term reduces their food intake and prevents weight gain, without leading to a slow-down in their metabolism.
“LCN2 acts as a signal for satiety after a meal, leading mice to limit their food intake, and it does this by acting on the hypothalamus within the brain,” explains lead author Peristera-Ioanna Petropoulou, who was a Postdoctoral Research Scientist at Columbia University Irving Medical Center, New York, US, at the time the study was carried out, and is now at the Helmholtz Diabetes Center, Helmholtz Zentrum München, Munich, Germany. “We wanted to see whether LCN2 has similar effects in humans, and whether a dose of it would be able to cross the blood-brain barrier.”
The team first analysed data from four different studies of people in the US and Europe who were either normal weight, overweight or living with obesity. The people in each study were given a meal after an overnight fast, and the amount of LCN2 in their blood before and after the meal was studied. The researchers found that in those who were of normal weight, there was an increase in LCN2 levels after the meal, which coincided with how satisfied they felt after eating.
By contrast, in people who were overweight or had obesity, LCN2 levels decreased after a meal. Based on this post-meal response, the researchers grouped people as non-responders or responders. Non-responders, who showed no increase in LCN2 after a meal, tended to have a larger waist circumference and higher markers of metabolic disease – including BMI, body fat, increased blood pressure and increased blood glucose. Remarkably, however, people who had lost weight after gastric bypass surgery were found to have a restored sensitivity to LCN2 – changing their status from non-responders before their surgery, to responders afterwards.
Taken together, these results mirror those seen in mice, and suggest that this loss of post-meal LCN2 regulation is a new mechanism contributing to obesity and could be a potential target for weight-loss treatments.
After verifying that LCN2 can cross into the brain, the team explored whether treatment with the hormone might reduce food intake and prevent weight gain. To do this, they treated monkeys with LCN2 for a week. They saw a 28% decrease in food intake compared with that before treatment within a week, and the monkeys also ate 21% less than their counterparts who were treated only with saline. Moreover, after only one week of treatment, measurements of body weight, body fat and blood fat levels showed a declining trend in treated animals.
“We have shown that LCN2 crosses to the brain, makes its way to the hypothalamus and suppresses food intake in non-human primates,” concludes senior author Stavroula Kousteni, Professor of Physiology and Cellular Biophysics at Columbia University Irving Medical Center. “Our results show that the hormone can curb appetite with negligible toxicity and lay the groundwork for the next level of LCN2 testing for clinical use.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Treatment for obesity
- 'Last acceptable form of bigotry:' Top doctor hopes to reduce obesity stigma
Believing more dialogue is necessary on the widespread issue, Chatham-Kent's top physician hopes to reduce stigma related to obesity. Believing more dialogue is necessary on the widespread issue, ...
- Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
While obesity and diabetes are the focus for now ... It is also pursuing a trial for kidney treatment. Eli Lilly, meanwhile, is currently testing Zepbound for sleep apnea.
- Walgreens partners with Boehringer Ingelheim on clinical trials for obesity treatment
The pharmacy retail giant has announced that it will partner with German pharmaceutical company Boehringer Ingelheim to leverage select Walgreens community pharmacies as clinical trial sites for ...
- Amgen’s obesity-drug stock surge still in ‘early innings,’ analysts say
Analysts see more gains ahead for Amgen after a stock surge fueled by upbeat comments on experimental obesity drug.
- Wegovy maker Novo Nordisk down 4%, heads for worst day since October
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Go deeper with Google Headlines on:
Treatment for obesity
[google_news title=”” keyword=”lithium” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Lipocalin-2
- Nintendo Switch 2 — rumors and everything we know so far
The Nintendo Switch 2 hasn't officially been announced but we've heard rumors about the handheld for more than a year at this point. Given how the Nintendo Switch is almost seven years old and ...
- When is the next Helldivers 2 update?
Helldivers 2 just received a major balancing patch, tweaking strategems, weapons and enemies. The Airburst Rocket Launcher is available for purchase, allowing you to fire a projectile which ...
- Is Helldivers 2 down? Current server status and error codes
Are the Helldivers 2 servers down? If you’re here searching for an answer, it could very well be obvious. Like any popular live service title, Helldivers 2 is prone to the odd blip from time to ...
- Pieris Pharmaceuticals gets grant for fusion polypeptide binding CD137 and GPC3 for cancer treatment
Discover the groundbreaking fusion polypeptide patent by Pieris Pharmaceuticals targeting CD137 and GPC3 for cancer treatment and immune modulation. Explore the innovative design and therapeutic ...
- 9 best 2-in-1 laptops in 2024: tested and reviewed
The 2-in-1 form factor has certainly come into its own over the last several years. There's really no reason to limit yourself to a clamshell, as there's a 2-in-1 that will meet the needs of all ...
Go deeper with Google Headlines on:
Lipocalin-2
[google_news title=”” keyword=”Lipocalin-2″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]